Neidio i'r cynnwys
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Uwch
  • S110: PHALLCON: A PHASE 3 STUD...
  • Dyfynnu hwn
  • Anfonwch hwn fel neges destun
  • E-bostio hwn
  • Argraffu
  • Allforio Cofnod
    • Allforio i RefWorks
    • Allforio i EndNoteWeb
    • Allforio i EndNote
  • Permanent link
S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Manylion Llyfryddiaeth
Prif Awduron: Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Wiley 2023-08-01
Cyfres:HemaSphere
Mynediad Ar-lein:http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0
  • Daliadau
  • Disgrifiad
  • Eitemau Tebyg
  • Dangos Staff

Rhyngrwyd

http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0

Eitemau Tebyg

  • PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
    gan: E. Jabbour, et al.
    Cyhoeddwyd: (2022-06-01)
  • Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
    gan: David Sanford, et al.
    Cyhoeddwyd: (2015-12-01)
  • The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
    gan: Aziz Nazha, et al.
    Cyhoeddwyd: (2013-10-01)
  • Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
    gan: Preetesh Jain, et al.
    Cyhoeddwyd: (2013-11-01)
  • P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
    gan: J. Apperley, et al.
    Cyhoeddwyd: (2022-06-01)

Opsiynau Chwilio

  • Hanes Chwilio
  • Chwiliad Uwch

Canfod Mwy

  • Pori'r Catalog
  • Pori yn ôl y Wyddor
  • Archwiliwch Sianeli
  • Cronfeydd y Cwrs
  • Eitemau Newydd

Angen Help?

  • Awgrymiadau Chwilio
  • Gofynnwch i Lyfrgellydd
  • Cwestiynau Cyffredin